Infectious Diseases

The biotech got a $176m award for its pandemic influenza vaccine program through BARDA’s Rapid Response Partnership Vehicle.

The green light from the European Commission for Ixchiq marks the third regulatory approval for the world’s first vaccine for chikungunya and extends the French biotech's lead over rival Bavarian Nordic.

The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.

In this week's podcast edition of Five Must-Know Things: the outlook for 2025 launches; Merck confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna missteps; and Sun’s North America head talks plans and strategy.

Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.

In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks. 

The company reported a late-stage success with its COVID-19 and flu combo vaccine, and says it can hit the market next year.

Shionogi says first major US R&D site will enhance capabilities for both Shionogi and its 2023 acquisition Qpex, which prompted the Japanese firm to build on the San Diego company's close research collaborations with US government organizations.

The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.

But it rescues embattled Novavax.

The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.